JPS6212205B2 - - Google Patents
Info
- Publication number
- JPS6212205B2 JPS6212205B2 JP54050758A JP5075879A JPS6212205B2 JP S6212205 B2 JPS6212205 B2 JP S6212205B2 JP 54050758 A JP54050758 A JP 54050758A JP 5075879 A JP5075879 A JP 5075879A JP S6212205 B2 JPS6212205 B2 JP S6212205B2
- Authority
- JP
- Japan
- Prior art keywords
- sah
- sleep
- administration
- induced
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims description 54
- 230000001939 inductive effect Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000005228 aryl sulfonate group Chemical group 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 13
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 12
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 11
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000036626 alertness Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000000537 electroencephalography Methods 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000001595 contractor effect Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- -1 briquettes Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000002567 electromyography Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000000803 paradoxical effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000000857 visual cortex Anatomy 0.000 description 2
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000424725 Heide Species 0.000 description 1
- 206010021089 Hyporeflexia Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003057 nialamide Drugs 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7812711A FR2424027A1 (fr) | 1978-04-28 | 1978-04-28 | Nouveau medicament, notamment sedatif et inducteur de sommeil et compositions pharmaceutiques la renfermant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS54145222A JPS54145222A (en) | 1979-11-13 |
| JPS6212205B2 true JPS6212205B2 (enExample) | 1987-03-17 |
Family
ID=9207735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5075879A Granted JPS54145222A (en) | 1978-04-28 | 1979-04-24 | Novel medicine * especially anodyne and sleep inducer and medical composition |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS54145222A (enExample) |
| BE (1) | BE875932A (enExample) |
| CH (1) | CH640137A5 (enExample) |
| DE (1) | DE2916880C2 (enExample) |
| FR (1) | FR2424027A1 (enExample) |
| GB (1) | GB2019720B (enExample) |
| IT (1) | IT1202914B (enExample) |
| LU (1) | LU81199A1 (enExample) |
| NL (1) | NL7903307A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10857592B2 (en) | 2013-07-11 | 2020-12-08 | Crucible Intellectual Property, LLC. | Manifold collar for distributing fluid through a cold crucible |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1193529B (it) * | 1980-04-22 | 1988-07-08 | Bioresearch Srl | Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo |
| JP2021046375A (ja) * | 2019-09-19 | 2021-03-25 | ポッカサッポロフード＆ビバレッジ株式会社 | β３アドレナリン受容体活性化剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2313937A1 (fr) * | 1975-06-09 | 1977-01-07 | Anvar | Medicament a base de 5' thioethers de l'adenosine |
-
1978
- 1978-04-28 FR FR7812711A patent/FR2424027A1/fr active Granted
-
1979
- 1979-04-24 JP JP5075879A patent/JPS54145222A/ja active Granted
- 1979-04-26 IT IT22168/79A patent/IT1202914B/it active
- 1979-04-26 CH CH394879A patent/CH640137A5/fr not_active IP Right Cessation
- 1979-04-26 NL NL7903307A patent/NL7903307A/xx not_active Application Discontinuation
- 1979-04-26 DE DE2916880A patent/DE2916880C2/de not_active Expired
- 1979-04-27 LU LU81199A patent/LU81199A1/xx unknown
- 1979-04-27 BE BE0/194901A patent/BE875932A/xx not_active IP Right Cessation
- 1979-04-30 GB GB7914876A patent/GB2019720B/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10857592B2 (en) | 2013-07-11 | 2020-12-08 | Crucible Intellectual Property, LLC. | Manifold collar for distributing fluid through a cold crucible |
Also Published As
| Publication number | Publication date |
|---|---|
| DE2916880A1 (de) | 1979-11-15 |
| GB2019720A (en) | 1979-11-07 |
| GB2019720B (en) | 1982-09-02 |
| BE875932A (fr) | 1979-08-16 |
| IT7922168A0 (it) | 1979-04-26 |
| IT1202914B (it) | 1989-02-15 |
| NL7903307A (nl) | 1979-10-30 |
| DE2916880C2 (de) | 1982-12-09 |
| FR2424027A1 (fr) | 1979-11-23 |
| CH640137A5 (fr) | 1983-12-30 |
| LU81199A1 (fr) | 1979-10-30 |
| JPS54145222A (en) | 1979-11-13 |
| FR2424027B1 (enExample) | 1981-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2201943B1 (en) | Novel use of a peptide class of compounds for treating diabetic neuropathic pain | |
| JP2025107355A (ja) | シクロベンザプリン塩酸塩の共融製剤 | |
| JP4259615B2 (ja) | 薬物常用および特にアルコール中毒の治寮へのγ―ヒドロキシ酪酸アミドの使用 | |
| CA2781436C (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
| JP2005527599A (ja) | 肥満および摂食障害におけるゾニサミドの使用 | |
| JP2005506320A (ja) | 新しいサイトカイン合成を阻害する抗炎症薬としてのヒドロキサム酸の、ヒストンデアセチラーゼ酵素を阻害する誘導体 | |
| TW201014839A (en) | Novel substituted sulfamide derivatives | |
| JP2009525979A (ja) | ４−アシルアミノピリジン誘導体を介した神経新生 | |
| JP2002518442A (ja) | 偏頭痛及び情動病の治療及び予防用バルプロ酸類似物の用法 | |
| WO2000041685A1 (en) | Ccr-3 receptor antagonists | |
| JPS6212205B2 (enExample) | ||
| JPH07505376A (ja) | 虚血および／または低酸素症の処置におけるフェノチアジン誘導体の使用 | |
| US3097136A (en) | Process for producing a depressant-like effect on the central nervous system | |
| JP2001507678A (ja) | 運動障害の治療のためのｎｋ−１受容体拮抗薬の使用 | |
| Branchey et al. | The effect of alpha-methyl-para-tyrosine on sleep and arousal in the rat | |
| EP0369286A2 (de) | Dibenzazepin-Derivate zur Behandlung von akuten und chronischen obstruktiven Atemwegserkrankungen | |
| JP2005538146A (ja) | 新規なピペリジン―２，６−ジオンパモエート塩類及びストレス関連情動性疾患を治療・処置するためにこれらを使用する方法 | |
| CA2405025A1 (en) | (2-aminoethyl) oxime derivatives for the treatment of depression | |
| AU2001255654A1 (en) | Materials and methods for the treatment of depression | |
| JPH04312585A (ja) | ピロリジン誘導体 | |
| JPS6081127A (ja) | 食欲抑制剤 | |
| US3094462A (en) | Therapeutic reaction complex for muscle relaxation | |
| JPS62234029A (ja) | 中枢神経賦活剤 | |
| JPS63152317A (ja) | 脳虚血性病変を伴う疾患治療剤 | |
| JP2021517134A (ja) | 癌、潰瘍性大腸炎、及び関連する炎症性疾患の処置に有用な方法、並びにイソインドリン−１，３−ジオン及びイソインドールプロドラッグの組成物 |